First Pulse: A Personal Journey in Cancer Research - Softcover

Über die Autorin bzw. den Autor

Dr. Merrill Garnett is the founder and CEO of Garnett McKeen Laboratory, Inc. Holding a D.D.S. from New York University, and graduate study in chemistry and biochemistry, Dr. Garnett has established research laboratories at the Central Islip State Hospital, Waldemar Medical Research Foundation, Northport Veterans' Administration Medical Center, and the High Technology Incubator of The State University of New York at Stony Brook.

Aus dem Klappentext

Merrill Garnett is a true original--a person in pursuit of a profoundly humane goal along career and personal paths quite unlike anyone else I have ever met. Merrill is one of the rare individuals for whom "doing well by doing good" isn't a superficial slogan but rather is truly second nature. In this book Merrill has produced a fascinating, intensely personal account of his 40 year quest for effective cancer treatments. I'm sure most readers will react to the book as I did. I was engaged and captivated--both at the personal and at the scientific levels. In this era of beaurocratized science, people like Merrill are increasingly rare and increasingly important. Readers are treated to a deep, clear look into this world.

--(Paul Bingham, Department of Biochemistry & Cell Biology, State University of New York at Stony Brook)

Auszug. © Genehmigter Nachdruck. Alle Rechte vorbehalten.

Throughout the years, I have looked for the developmental enzymes. These are mystery enzymes. Everybody wants to know why the cell develops into something different. As you grow older, you become a different creature. We can only study the individual reactions that are definable and clear, but in the cell we have a concert being played. It has a prelude in the baby and the small child, then an overture in the adolescent, then the recurring themes of the mature adult and finally the old--all because of the mystery developmental enzymes. Now I'm not saying that the enzymes turn on and off. A new enzyme comes on the stage. There are new players as the drama unfolds. It's gene expression, and what we bring here to genetics is the suggestion that the developmental reactions rely heavily on energy. I refer to this as electrogenetics. Electrogenetics is a new subject. There are three enzymes that I have copied in catalytic ways which seem to cause development, and which can be used to treat tumors. But that's just the tip of the iceberg...

...I see cancer as an embryo cell that can't make the next transition. This idea of disease as a failure to mature is an old one, and it has to be clarified in detail. There are three major events in maturation that i know of (and I'm sure there are many more that I haven't considered) that have to do with energy flow in the cell. There are a number of major enzymatic events that have to be expressed in order for energy to flow. That's just to get started. And then for the maintenance of that flow there's an enormous number of, shall we say, stock enzymes that run to do the job. So when the impedance is wrong--impedance being the current at that resistance which is dependent on particular frequencies for its transmission--or the wire breaks, you have to change the impedance or restore the connection. This is what palladium DNA reductase, the molecule we developed in the 1990s, does.

The discovery of the palladium complex as a therapeutic metallo-organic agent suggests that there are many more mysterious catalytic metals that may well be utilized by living organisms for growth. There also may be alternative pathways that can be substituted for existing enzymes in case there are genetic defects. The periodic table is so extensive it invites a great deal of work with metals in the body. What we're now trying to do is to discover the electrical schematic at the cellular level. I never dreamed that the reactions were so organized and concerted. What we have in the palladium complex is a molecular electronic device.